{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T17:20:49Z","timestamp":1794590449167,"version":"4.9.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,25]],"date-time":"2025-05-25T00:00:00Z","timestamp":1748131200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,25]],"date-time":"2025-05-25T00:00:00Z","timestamp":1748131200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pneumonia"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>This real-world study aimed to assess the effectiveness of novel oral antiviral agents in managing COVID-19 among high-risk patients during the Omicron JN.1 subvariant wave.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Data from the TriNetX US network were analyzed using a multi-institutional propensity score matching (PSM) analysis. High-risk non-hospitalized adults with COVID-19 were included, and patients receiving oral antiviral agents (study group) were compared to those not receiving antiviral agents (control group). Primary outcomes included all-cause emergency department (ED) visits, hospitalizations, or death within 30\u00a0days.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Among 67,495 high-risk patients identified, 17,852 received oral antiviral agents (study group) and 49,643 did not (control group). After PSM, two matched cohorts of 17,847 patients each were established. The study group receiving antiviral agents exhibited a significantly lower risk of primary composite outcome during the 30-day follow-up period compared to the control group (HR, 0.77; 95% CI, 0.72\u20130.84). Regarding the secondary outcomes, the study group consistently exhibited a significantly lower risk of all-cause ED visits (4.2% vs. 5.4%; HR, 0.78; 95% CI, 0.71\u20130.86), hospitalization (2.8% vs. 3.3%; HR, 0.86; 95% CI, 0.77\u20130.97), and mortality (0.1% vs. 0.3%; HR, 0.17; 95% CI, 0.08\u20130.35) than the control group. Subgroup analyses showed consistent benefits across various demographic and clinical characteristics, except in individuals with booster vaccination.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Oral antiviral agents significantly reduced the risk of adverse outcomes among high-risk COVID-19 patients during the Omicron JN.1 subvariant wave. These findings support the potential benefits of oral antiviral therapy in treating COVID-19, particularly in high-risk populations.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s41479-025-00168-w","type":"journal-article","created":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T23:01:57Z","timestamp":1748127717000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Clinical effectiveness of oral antiviral treatment for non-hospitalized high-risk patients with COVID-19 during Omicron JN.1 subvariant wave: a US-based propensity-matched cohort study"],"prefix":"10.1186","volume":"17","author":[{"given":"Wan-Hsuan","family":"Hsu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo-Wen","family":"Shiau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Yu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Wen","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jheng-Yan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting-Hui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Hsiang","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Farn","family":"Tey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lun-Wu","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Cheng","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,25]]},"reference":[{"key":"168_CR1","doi-asserted-by":"publisher","first-page":"105924","DOI":"10.1016\/j.ijantimicag.2020.105924","volume":"55","author":"CC Lai","year":"2020","unstructured":"Lai CC, Shih TP, Ko WC, et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents. 2020;55:105924.","journal-title":"Int J Antimicrob Agents"},{"key":"168_CR2","doi-asserted-by":"publisher","first-page":"105946","DOI":"10.1016\/j.ijantimicag.2020.105946","volume":"55","author":"CC Lai","year":"2020","unstructured":"Lai CC, Wang CY, Wang YH, et al. Global epidemiology of coronavirus disease 2019 (COVID-19): disease incidence, daily cumulative index, mortality, and their association with country healthcare resources and economic status. Int J Antimicrob Agents. 2020;55:105946.","journal-title":"Int J Antimicrob Agents"},{"key":"168_CR3","unstructured":"World Health Organization. https:\/\/data.who.int\/dashboards\/covid19\/cases. Accessed 9 May 2024."},{"key":"168_CR4","doi-asserted-by":"crossref","unstructured":"Jeworowski LM, M\u00fchlemann B, Walper F, et al. Humoral immune escape by current SARS-CoV-2 variants BA.2.86 and JN.1, December 2023. Euro Surveill. 2024;29:2300740.","DOI":"10.2807\/1560-7917.ES.2024.29.2.2300740"},{"key":"168_CR5","doi-asserted-by":"publisher","first-page":"e82","DOI":"10.1016\/S1473-3099(23)00813-7","volume":"24","author":"Y Kaku","year":"2024","unstructured":"Kaku Y, Okumura K, Padilla-Blanco M, et al. Virological characteristics of the SARS-CoV-2 JN.1 variant. Lancet Infect Dis. 2024;24:e82.","journal-title":"Lancet Infect Dis"},{"key":"168_CR6","doi-asserted-by":"crossref","unstructured":"Planas D, Staropoli I, Michel V, et al. Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86\/JN.1 lineages combining increased fitness and antibody evasion. Nat Commun. 2024;15:2254.","DOI":"10.1038\/s41467-024-46490-7"},{"key":"168_CR7","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.it.2024.01.003","volume":"45","author":"X Wang","year":"2024","unstructured":"Wang X, Lu L, Jiang S. SARS-CoV-2 evolution from the BA.2.86 to JN.1 variants: unexpected consequences. Trends Immunol. 2024;45:81\u20134.","journal-title":"Trends Immunol"},{"key":"168_CR8","doi-asserted-by":"publisher","first-page":"2975","DOI":"10.1136\/bmj.p2975","volume":"383","author":"MK Looi","year":"2023","unstructured":"Looi MK. Covid-19: WHO adds JN.1 as new variant of interest. BMJ. 2023;383:2975.","journal-title":"BMJ"},{"key":"168_CR9","doi-asserted-by":"crossref","unstructured":"Bartel A, Grau JH, Bitzegeio J, et al. Timely Monitoring of SARS-CoV-2 RNA Fragments in Wastewater Shows the Emergence of JN.1 (BA.2.86.1.1, Clade 23I) in Berlin, Germany. Viruses. 2024;16:102.","DOI":"10.3390\/v16010102"},{"key":"168_CR10","doi-asserted-by":"crossref","unstructured":"Jony MHK, Alam AN, Nasif MAO, et al. Emergence of SARS-CoV-2 Omicron sub-lineage JN.1 in Bangladesh. Microbiol Resour Announc. 2024;13:e0013024.","DOI":"10.1128\/mra.00130-24"},{"key":"168_CR11","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1001\/jama.2023.27841","volume":"331","author":"R Rubin","year":"2024","unstructured":"Rubin R. As COVID-19 Cases surge, here\u2019s what to know about JN.1, the latest SARS-CoV-2 \u201cVariant of Interest.\u201d JAMA. 2024;331:382\u20133.","journal-title":"JAMA"},{"key":"168_CR12","doi-asserted-by":"crossref","unstructured":"Selvavinayagam ST, Sankar S, Yong YK, et al. Emergence of SARS-CoV-2 Omicron Variant JN.1 in Tamil Nadu, India - Clinical Characteristics and Novel Mutations. Sci Rep. 2024;14:17476.","DOI":"10.1038\/s41598-024-68678-z"},{"key":"168_CR13","doi-asserted-by":"publisher","first-page":"67","DOI":"10.5582\/ddt.2024.01008","volume":"18","author":"G Ou","year":"2024","unstructured":"Ou G, Yang Y, Zhang S, et al. Evolving immune evasion and transmissibility of SARS-CoV-2: The emergence of JN.1 variant and its global impact. Drug Discov Ther. 2024;18:67\u201370.","journal-title":"Drug Discov Ther"},{"key":"168_CR14","doi-asserted-by":"publisher","first-page":"101225","DOI":"10.1016\/j.nmni.2024.101225","volume":"57","author":"P Satapathy","year":"2024","unstructured":"Satapathy P, Kumar P, Mehta V, et al. Global spread of COVID-19\u2019s JN.1 variant: implications and public health responses. New Microbes New Infect. 2024;57:101225.","journal-title":"New Microbes New Infect"},{"key":"168_CR15","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.jmii.2020.02.012","volume":"53","author":"CC Lai","year":"2020","unstructured":"Lai CC, Liu YH, Wang CY, et al. Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths. J Microbiol Immunol Infect. 2020;53:404\u201312.","journal-title":"J Microbiol Immunol Infect"},{"key":"168_CR16","first-page":"100693","volume":"31","author":"NR Aggarwal","year":"2024","unstructured":"Aggarwal NR, Beaty LE, Bennett TD, et al. Real-world use of nirmatrelvir-ritonavir in COVID-19 outpatients during BQ.1, BQ.1.1., and XBB.1.5 predominant omicron variants in three U.S. health systems: a retrospective cohort study. Lancet Reg Health Am. 2024;31:100693.","journal-title":"Lancet Reg Health Am"},{"key":"168_CR17","doi-asserted-by":"crossref","unstructured":"Hsu CK, Hsu WH, Shiau BW, et al. The effectiveness of novel oral antiviral treatment for non-hospitalized high-risk patients with COVID-19 during predominance of omicron XBB subvariants. Expert Rev Anti Infect Ther. 2024;22:785\u201392.","DOI":"10.1080\/14787210.2024.2339398"},{"key":"168_CR18","doi-asserted-by":"publisher","first-page":"e2335077","DOI":"10.1001\/jamanetworkopen.2023.35077","volume":"6","author":"DY Lin","year":"2023","unstructured":"Lin DY, Abi Fadel F, Huang S, et al. Nirmatrelvir or Molnupiravir use and severe outcomes from omicron infections. JAMA Netw Open. 2023;6:e2335077.","journal-title":"JAMA Netw Open"},{"key":"168_CR19","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ijid.2023.08.003","volume":"135","author":"EV Low","year":"2023","unstructured":"Low EV, Pathmanathan MD, Chidambaram SK, et al. Real-world nirmatrelvir-ritonavir outpatient treatment in reducing hospitalization for high-risk patients with COVID-19 during Omicron BA.4, BA.5\u00a0and XBB subvariants dominance in Malaysia: a retrospective cohort study. Int J Infect Dis. 2023;135:77\u201383.","journal-title":"Int J Infect Dis"},{"key":"168_CR20","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1016\/j.cmi.2023.06.016","volume":"29","author":"LE Wee","year":"2023","unstructured":"Wee LE, Tay AT, Chiew C, et al. Real-world effectiveness of nirmatrelvir\/ritonavir against COVID-19 hospitalizations and severe COVID-19 in community-dwelling elderly Singaporeans during Omicron BA.2, BA.4\/5, and XBB transmission. Clin Microbiol Infect. 2023;29:1328\u201333.","journal-title":"Clin Microbiol Infect"},{"key":"168_CR21","doi-asserted-by":"publisher","first-page":"ooad035","DOI":"10.1093\/jamiaopen\/ooad035","volume":"6","author":"MB Palchuk","year":"2023","unstructured":"Palchuk MB, London JW, Perez-Rey D, et al. A global federated real-world data and analytics platform for research. JAMIA Open. 2023;6:ooad035.","journal-title":"JAMIA Open"},{"key":"168_CR22","unstructured":"Centers for Disease Control and Prevention. COVID Data Tracker: Variant Proportions. https:\/\/covid.cdc.gov\/covid-data-tracker\/#variant-proportions. Accessed on 1 May 2024."},{"key":"168_CR23","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1093\/aje\/kwv254","volume":"183","author":"MA Hern\u00e1n","year":"2016","unstructured":"Hern\u00e1n MA, Robins JM. Using big data to emulate a target trial when a randomized trial is not available. Am J Epidemiol. 2016;183:758\u201364.","journal-title":"Am J Epidemiol"},{"key":"168_CR24","unstructured":"CDC. Underlying conditions and the higher risk for severe covid-19. 2025 February 6, 2025. Available from: https:\/\/www.cdc.gov\/covid\/hcp\/clinical-care\/underlying-conditions.html. Cited 2025 March 11."},{"key":"168_CR25","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1080\/14787210.2023.2267846","volume":"21","author":"WH Hsu","year":"2023","unstructured":"Hsu WH, Shiau BW, Liu TH, et al. Clinical effectiveness of nirmatrelvir plus ritonavir in the treatment of COVID-19 in patients with cirrhosis. Expert Rev Anti Infect Ther. 2023;21:1143\u201351.","journal-title":"Expert Rev Anti Infect Ther"},{"key":"168_CR26","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.jinf.2023.03.016","volume":"87","author":"WH Hsu","year":"2023","unstructured":"Hsu WH, Shiau BW, Tsai YW, et al. The effect of molnupiravir on post-acute outcome of COVID-19 survivors. J Infect. 2023;87:339\u201343.","journal-title":"J Infect"},{"key":"168_CR27","doi-asserted-by":"publisher","first-page":"e28750","DOI":"10.1002\/jmv.28750","volume":"95","author":"MH Chuang","year":"2023","unstructured":"Chuang MH, Wu JY, Liu TH, et al. Efficacy of nirmatrelvir and ritonavir for post-acute COVID-19 sequelae beyond 3 months of SARS-CoV-2 infection. J Med Virol. 2023;95:e28750.","journal-title":"J Med Virol"},{"key":"168_CR28","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1001\/jama.2015.13480","volume":"314","author":"JS Haukoos","year":"2015","unstructured":"Haukoos JS, Lewis RJ. The Propensity Score Jama. 2015;314:1637\u20138.","journal-title":"The Propensity Score Jama"},{"key":"168_CR29","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/S1473-3099(23)00011-7","volume":"23","author":"NR Aggarwal","year":"2023","unstructured":"Aggarwal NR, Molina KC, Beaty LE, et al. Real-world use of nirmatrelvir-ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study. Lancet Infect Dis. 2023;23:696\u2013705.","journal-title":"Lancet Infect Dis"},{"key":"168_CR30","doi-asserted-by":"publisher","first-page":"77","DOI":"10.7326\/M22-2141","volume":"176","author":"S Dryden-Peterson","year":"2023","unstructured":"Dryden-Peterson S, Kim A, Kim AY, et al. Nirmatrelvir plus ritonavir for early COVID-19 in a large U.S. health system: a population-based cohort study. Ann Intern Med. 2023;176:77\u201384.","journal-title":"Ann Intern Med"},{"key":"168_CR31","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1093\/cid\/ciac673","volume":"76","author":"S Ganatra","year":"2023","unstructured":"Ganatra S, Dani SS, Ahmad J, et al. Oral nirmatrelvir and ritonavir in nonhospitalized vaccinated patients with coronavirus disease 2019. Clin Infect Dis. 2023;76:563\u201372.","journal-title":"Clin Infect Dis"},{"key":"168_CR32","doi-asserted-by":"publisher","first-page":"e148","DOI":"10.1093\/cid\/ciac600","volume":"76","author":"H Li","year":"2023","unstructured":"Li H, Gao M, You H, et al. Association of nirmatrelvir\/ritonavir treatment on upper respiratory Severe Acute Respiratory Syndrome Coronavirus 2 Reverse Transcription-Polymerase Chain Reaction (SARS-Cov-2 RT-PCR) negative conversion rates among high-risk patients with coronavirus disease 2019 (COVID-19). Clin Infect Dis. 2023;76:e148\u201354.","journal-title":"Clin Infect Dis"},{"key":"168_CR33","doi-asserted-by":"publisher","first-page":"e28497","DOI":"10.1002\/jmv.28497","volume":"95","author":"T Qi","year":"2023","unstructured":"Qi T, Jin Y, Wang H, et al. Nirmatrelvir-ritonavir therapy and COVID-19 vaccination improve clinical outcomes of SARS-CoV-2 Omicron variant infection. J Med Virol. 2023;95:e28497.","journal-title":"J Med Virol"},{"key":"168_CR34","first-page":"100602","volume":"30","author":"AK Wai","year":"2023","unstructured":"Wai AK, Chan CY, Cheung AW, et al. Association of Molnupiravir and Nirmatrelvir-Ritonavir with preventable mortality, hospital admissions and related avoidable healthcare system cost among high-risk patients with mild to moderate COVID-19. Lancet Reg Health West Pac. 2023;30:100602.","journal-title":"Lancet Reg Health West Pac"},{"key":"168_CR35","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1093\/cid\/ciac687","volume":"76","author":"TC Yip","year":"2023","unstructured":"Yip TC, Lui GC, Lai MS, et al. Impact of the use of oral antiviral agents on the risk of hospitalization in community coronavirus disease 2019 patients (COVID-19). Clin Infect Dis. 2023;76:e26\u201333.","journal-title":"Clin Infect Dis"},{"key":"168_CR36","doi-asserted-by":"publisher","first-page":"e28869","DOI":"10.1002\/jmv.28869","volume":"95","author":"YW Tsai","year":"2023","unstructured":"Tsai YW, Wu JY, Liu TH, et al. Clinical effectiveness of oral antiviral agents in older patients with COVID-19 based on real-world data. J Med Virol. 2023;95:e28869.","journal-title":"J Med Virol"},{"key":"168_CR37","doi-asserted-by":"publisher","first-page":"e29662","DOI":"10.1002\/jmv.29662","volume":"96","author":"JY Wu","year":"2024","unstructured":"Wu JY, Chen CC, Liu MY, et al. Clinical effectiveness of nirmatrelvir plus ritonavir on the short- and long-term outcome in high-risk children with COVID-19. J Med Virol. 2024;96:e29662.","journal-title":"J Med Virol"},{"key":"168_CR38","doi-asserted-by":"publisher","first-page":"e28866","DOI":"10.1002\/jmv.28866","volume":"95","author":"JY Wu","year":"2023","unstructured":"Wu JY, Liu MY, Liu TH, et al. Clinical efficacy of nirmatrelvir and ritonavir combination for treating diabetic patients with COVID-19. J Med Virol. 2023;95:e28866.","journal-title":"J Med Virol"},{"key":"168_CR39","doi-asserted-by":"publisher","first-page":"106984","DOI":"10.1016\/j.ijantimicag.2023.106984","volume":"62","author":"JY Wu","year":"2023","unstructured":"Wu JY, Liu MY, Liu TH, et al. Association between nirmatrelvir plus ritonavir and the outcomes of non-hospitalized obese patients with COVID-19. Int J Antimicrob Agents. 2023;62:106984.","journal-title":"Int J Antimicrob Agents"},{"key":"168_CR40","doi-asserted-by":"publisher","first-page":"1321155","DOI":"10.3389\/fphar.2024.1321155","volume":"15","author":"CC Yang","year":"2024","unstructured":"Yang CC, Tsai YW, Wang SH, et al. The effectiveness of oral anti-SARS-CoV-2 agents in non-hospitalized COVID-19 patients with nonalcoholic fatty liver disease: a retrospective study. Front Pharmacol. 2024;15:1321155.","journal-title":"Front Pharmacol"}],"container-title":["Pneumonia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41479-025-00168-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41479-025-00168-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41479-025-00168-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T23:02:00Z","timestamp":1748127720000},"score":1,"resource":{"primary":{"URL":"https:\/\/pneumonia.biomedcentral.com\/articles\/10.1186\/s41479-025-00168-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,25]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["168"],"URL":"https:\/\/doi.org\/10.1186\/s41479-025-00168-w","relation":{},"ISSN":["2200-6133"],"issn-type":[{"value":"2200-6133","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,25]]},"assertion":[{"value":"29 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with in accordance with the Declaration of Helsinki. Written informed consent was not required because TriNetX contains anonymized data. The Institutional Review Board of the Chi Mei Medical Center approved the study protocol (no. 11202\u2013002).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"No.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12"}}